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Background: The mechanisms of versican proteolysis by ADAMTS proteases are unknown.
Results: The ADAMTS5 ancillary domain and specific chondroitin sulfate chains of versican are required for proteolysis.
Conclusion: Docking between the ADAMTS5 ancillary domain and CS chains is a major mechanism underlying versican
proteolysis. Proteolysis by ADAMTS1 has a similar requirement for GAG chains.
Significance: The findings suggest strategies for blocking versican cleavage.
Proteolysis of the Glu441-Ala442 bond in the glycosaminogly-
can (GAG) domain of the versican-V1 variant by a disintegrin-
like andmetalloproteinase domainwith thrombospondin type 1
motif (ADAMTS) proteases is required for proper embryomor-
phogenesis. However, the processing mechanism and the possi-
bility of additional ADAMTS-cleaved processing sites are
unknown. We demonstrate here that if Glu441 is mutated,
ADAMTS5 cleaves inefficiently at a proximate upstream site
but normally does not cleave elsewhere within the GAG
domain. Chondroitin sulfate (CS) modification of versican is a
prerequisite for cleavage at the Glu441-Ala442 site, as demon-
strated by reduced processing of CS-deficient or chondroitinase
ABC-treated versican-V1. Site-directed mutagenesis identified
the N-terminal CS attachment sites Ser507 and Ser525 as essen-
tial for processing of the Glu441-Ala442 bond by ADAMTS5. A
construct including only these two GAG chains, but not down-
stream GAG attachment sites, was cleaved efficiently. There-
fore, CS chain attachment to Ser507 and Ser525 is necessary and
sufficient for versicanproteolysis byADAMTS5.Mutagenesis of
Glu441 and an antibody to a peptide spanning Thr432-Gly445 (i.e.
containing the scissile bond) reduced versican-V1 processing.
ADAMTS5 lacking the C-terminal ancillary domain did not
cleave versican, and an ADAMTS5 ancillary domain construct
bound versican-V1 via the CS chains.We conclude that docking
of ADAMTS5 with two N-terminal GAG chains of versican-V1
via its ancillary domain is required for versican processing at
Glu441-Ala442. V1 proteolysis by ADAMTS1 demonstrated a
similar requirement for the N-terminal GAG chains andGlu441.
Therefore, versican cleavage can be inhibited substantially by
mutation of Glu441, Ser507, and Ser525 or by an antibody to the
region of the scissile bond.
Versican is a member of a family of large aggregating pro-
teoglycans (termed lecticans) present in the extracellular
matrix that includes aggrecan, brevican, and neurocan (1).
These proteoglycans have a similar structure, comprising a
globular N-terminal domain (G1), a central glycosaminoglycan
(GAG)2 domain containing attachment sites for GAG chains,
and a globular C-terminal domain (G3) (2). Aggrecan alone has
an additional globular domain (G2) that lies between the G1
and G3 domains on the N-terminal side of its GAG domain.
The predominant GAG present in these proteoglycans is chon-
droitin sulfate (CS). Through their G1 domains, these pro-
teoglycans bind to hyaluronan, an interaction that is stabilized
by link protein, forming largemultimeric complexes that inter-
act with cell surface hyaluronan receptors such as CD44 (3–5).
The versican G3 domain binds to fibulin 1 and 2, fibrillin 1, and
tenascin C and R (6–8). Versican is a component of the peri-
cellular matrix as well as the interstitial extracellular matrix
networks (9–11). Versican is widely expressed in embryonic
and extraembryonic tissues (12–14), whereas aggrecan is spe-
cific for cartilage and the central nervous system, and brevican
and neurocan are only found in the central nervous system (1).
As a component of embryonic cardiac jelly, the interdigit mes-
enchyme, and the prechondrogenic mesenchyme of the limb,
hyaluronan-versican complexes have crucial roles in embryo-
genesis (3, 15–22) and in regulating cell migration, prolifera-
tion, and apoptosis (9, 20, 23–25). Versican is present in adult
vasculature, skin, and the central nervous system, as well as in
solid tumors of several organs (26–29). Versican has several
splice isoforms arising from alternative splicing of two large
exons encoding CS attachment domains, termed GAG and
GAG (30–32). These variants are V0 (containing GAG and
GAG), V1 (containing GAG only), V2 (containing GAG
only), and V3, lacking either GAG domain. V2 is primarily
found in the central nervous system and V0 in the nervous and* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
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cardiovascular systems, butV1 iswidely expressed, especially in
the embryo (12, 13, 26, 33–36). V3 expression and localization
are poorly defined. Recently, a new variant, V4, generated by
splicing at a cryptic site within the GAG domain, has been
identified in cancer cells (28).
ADAMTS proteases cleave aggrecan at multiple sites, an
activity named aggrecanase, which is a major contributor to
cartilage destruction in osteoarthritis (37–39). Among these
sites, one within the aggrecan G1-G2 interglobular domain
(Glu374-Ala375) was deemed critical because it released the
entire GAG domain (40). Additional ADAMTS cleavage sites
have been identified within the GAG-bearing domain (39).
Although aggrecanase sites lack a sequence consensus, Sandy et
al. (35) noticed a preference for ADAMTS cleavage after gluta-
mate residues and predicted a cleavage site in versican-V1 cor-
responding to the aggrecan interglobular domain by compari-
son of versican and aggrecan core protein sequences. They
generated a neoepitope antibody recognizing the predicted new
C terminus generated after ADAMTS cleavage, i.e. the
sequence DPEAAE441 (corresponding to DPEAAE1428 in V0)
(35).
The predicted scissile bond Glu441-Ala442 was cleaved by
ADAMTS1 and ADAMTS4, and this versicanase activity has
been detected in the aortic intima (35). Subsequently,
ADAMTS5, ADAMTS9, ADAMTS15, and ADAMTS20 have
been found to cleave this site (41–43). Analysis of mice lacking
Adamts1, Adamts5, Adamts9, and Adamts20 identified anom-
alies in ovulation, interdigital web regression, skin pigmenta-
tion, cardiac development, and palate formation thatwere asso-
ciated with reduced versican processing (16, 17, 19, 33, 44–48).
The N-terminal V1 fragment extending to DPEAAE441 and
now termed versikine (19) induced apoptosis in Adamts5
Adamts20-deficient interdigital webs, which failed to undergo
regression because of reduced extracellular matrix breakdown
and apoptosis (17). Therefore, a major physiological role that
has emerged for several ADAMTS proteases is processing of
versican during embryogenesis, although it remains unclear
whether versican is the only substrate that explains develop-
mental defects in ADAMTS gene mutants.
Despite the exceptional biological relevance of versican pro-
cessing by ADAMTS proteases, it is a poorly understood pro-
cess. Among the questions that have not been addressed are
whether versican is cleaved at additional sites in the core pro-
tein and which molecular determinants in versican or
ADAMTS proteases are crucial for the enzyme-substrate inter-
action and proteolysis. This knowledge would offer potential
means to block versican processing as a way of further investi-
gating the biological relevance of versican processing. Collec-
tively, these unresolved questions motivated this analysis of
versican-V1 processing by ADAMTS5.
EXPERIMENTAL PROCEDURES
ADAMTS and Versican Expression Plasmids and Site-di-
rected Mutagenesis—Mammalian expression plasmids for
ADAMTS1 and ADAMTS5 expression have been described
previously (41, 49). A versican-V1 plasmid in vector pSecTagA
(Invitrogen), the versican V4 expression plasmid, and the
G1-DPEAAE plasmid made by inserting a stop codon after
Glu441 have been published previously (17, 28, 50). The V1
expression plasmid had an intervening 3-untranslated
sequence between the stop codon and the epitope tags. There-
fore, an XhoI restriction site was inserted to disrupt the stop
codon using the QuikChange mutagenesis kit (Stratagene,
Santa Clara, CA), the 3-untranslated sequence was excised,
and the plasmid was religated to render the versican ORF con-
tinuous with the myc and His6 tags. To generate the constructs
V-5GAG-myc, V-2GAG-myc, and DPEAAE-myc (Fig. 1A), a
second XhoI site was placed at the appropriate location within
the versican ORF. Mutagenized plasmids were digested with
XhoI, and the region between the twoXhoI sites was eliminated
by agarose electrophoresis followed by religation of the plas-
mids. Specific glycine or serine residues within four N-terminal
GAG attachment sites (i.e. Ser-Gly or Gly-Ser motifs within an
acidic sequence consensus) (2) in the V-5GAG construct were
mutated by site-directed mutagenesis (Ser507 to Ala, Ser525 to
Gly, Gly645 to Val, and Ser655 to Ala). Residues around the
Glu441-Ala442 scissile bond were mutated using the QuikChange
mutagenesis kit (Stratagene). All introducedmutations were veri-
fied by nucleotide sequencing.
Cell Culture, Transfections, andEnzymaticDeglycosylation—
HEK293F cells (ATCC)were cultured inDMEMsupplemented
with 10% FBS and antibiotics. CHO-K1 and pgsA-745 cells
(ATCC) (51) were cultured in 1:1 Ham’s F12 and DMEM sup-
plemented with 10% FBS and antibiotics. ADAMTS and versi-
can expression plasmids were transiently transfected or
cotransfected using FuGENE6 (Roche Diagnostics). Condi-
tioned medium from empty vector (pcDNA3.1 MycHis, Invit-
rogen)-transfected cells was used as the control in versican
digests. Serum-free medium was collected from transfected
cells after 48 h. Cells were lysed in 1% (w/v) Triton X-100,
10 mM Tris HCl (pH 7.6) containing complete protease inhibi-
tor mixture (Roche Diagnostics) to obtain a cell lysate. To
detect N-glycosylation of the versikine-myc construct, it was
reduced by addition of 2% 2-mercaptoethanol and boiling for 5
min prior to incubation with peptideN-glycanase F (New Eng-
land Biolabs, Ipswich, MA) for 2 h at 37 °C. Unless specified
otherwise, reagents were from Sigma-Aldrich (St. Louis, MO).
Generation of Anti-VC, a Cleavage-blocking Versican Poly-
clonal Antibody—Anti-VCwas generated in rabbits against the
peptide sequence NH2-(C)T432VPKDPEAAEARRG445-COOH
spanning the ADAMTS cleavage site (in italics) in the versi-
can-V1 core protein. TheN-terminal Cys residuewas added for
conjugation to keyhole limpet hemocyanin, and the keyhole
limpet hemocyanin-peptide conjugate was injected into rabbits
(YenZymAntibodies, LLC, South San Francisco, CA). Immune
sera were affinity-purified against the immobilized peptide
antigen. To block ADAMTS5 cleavage of versican V5-GAG,
anti-VC was incubated with V-5GAG at increasing concentra-
tions for 30 min at 37 °C. These V-5GAG-anti-VC complexes
were then used in subsequent versican digestion (versicanase)
assays.
Characterization of Anti-DPEAAE Specificity—NH2-DPEAAE-
COOH peptide or variations of it were synthesized by the
Lerner Research Institute Molecular Biotechnology Core. Ver-
sikine-containing conditioned mediumwas diluted 1:2 in coat-
ing buffer (40 mM Na2CO3 (pH 9.6)), and 200 l was used to
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coat F96 Maxisorb plates (Nunc, Rochester, NY) by overnight
incubation at room temperature. The wells were washed with
50 mM HEPES, 100 mM NaCl, 0.05% (v/v) Tween 20 (pH 7.4),
blocked by incubating with 200 l of 1% (w/v) BSA (2 h, 37 °C),
and the washing steps were repeated. Anti-DPEAAE (Affinity
Bioreagents, Golden, CO) was preincubated with increasing
concentrations of the peptides for 30 min at 37 °C. These were
incubated with the versikine-coated wells (4 h, 37 °C) and
washed. Alkaline phosphatase-conjugated rabbit antibody
(Bio-Rad)was added to eachwell (2 h, 37 °C) and detected using
p-nitrophenyl phosphate tablets (Sigma) and detection of the
product at A405.
Quantification of ADAMTS5 Concentration—ADAMTS5
concentration in the single batch of HEK293F conditioned
medium used for this study was determined using a solid phase
binding assay. Purified, recombinant ADAMTS5 Pro-Cat-Dis
(provided by Dr. David Buttle, Sheffield University, UK) was
coated overnight (in coating buffer) on F96 Maxisorb plates at
increasing concentrations alongside multiple dilutions of
ADAMTS5 conditioned medium. The wells were washed and
blocked as described above, andADAMTS5was detected using
12F4, a monoclonal antibody with a conformational epitope
spanning the catalytic and disintegrin-like domains (Glaxo-
SmithKline, King of Prussia, PA).3 Anti-mouse alkaline phos-
phatase-conjugated antibody (Bio-Rad) was added, and the
bound antibody was detected using p-nitrophenyl phosphate
tablets. Nonspecific antibody interactions were accounted for
by subtracting the absorbance of wells coated with empty
vector control conditioned medium. The concentration of
ADAMTS5 was deduced from the monoclonal antibody-bind-
ing curve generated from the absorbance at 405 nm of the
recombinant protein. This gave a value of 3 g/ml. For all
versican digests, 100l of conditionedmediumwas used (300
ng of ADAMTS5).
Versican Antibodies, Versican Digestion, Western Blotting,
and Densitometry—To detect versicanase activity, conditioned
medium fromADAMTS transfections was combined with ver-
sican conditioned medium in a 1:1 ratio, incubated for 16 h at
37 °C, and analyzed using 10% SDS-PAGE. Alternatively,
HEK293Fcells were cotransfectedwith 1g each ofADAMTS5
and versican plasmids, and the conditioned medium was ana-
lyzed as above.Western blotting was done under reducing con-
ditions using anti-VC or anti-DPEAAE; anti-GAG (Millipore-
Chemicon, Temecula, CA, 1 g/ml); rabbit anti-G1 domain
polyclonal antibody (provided by Dr. John Sandy, Rush Univer-
sity Medical Center, Chicago, IL); anti-myc monoclonal anti-
body 9E10 (Invitrogen); anti-His6 (R&D Systems, Minneapolis,
MN); or polyclonal rabbit antisera anti-GAG A (against
amino acids 357–567) (14), anti-GAG B (against amino acids
654–847),4 anti-GAG C (against amino acids 1028–1274)
(Dours-Zimmermann, M.T. and Zimmermann, D.R., unpub-
lished), and anti-GAG D (against amino acids 1659–2101)
(14) and enhanced chemiluminescence (GE Healthcare). Band
intensity was quantitated using ImageJ software (National
Institutes of Health, Bethesda, MD). To quantify versicanase
activity in some assays, the band intensity obtained with anti-
DPEAAE was divided by the band intensity of versican
(V-5GAG) in the conditioned medium using anti-myc to give a
relative intensity ratio. The protein content of V-5GAG,
V-2GAG, and versican-V1within the conditionedmediumwas
determined by treating with chondroitinase ABC (Seikagaku,
Tokyo, Japan) at a concentration of 0.1 units/ml for 2 h at 37 °C,
and analyzed by 6% SDS-PAGE and Western blotting as
described above.
Synthesis of Click-xyloside and Xyloside Treatment of Cells—
Click-xyloside synthesis was as described previously (52).
Briefly, copper-catalyzed click chemistry was performed at
room temperature in 1:1 acetone:water. 1.2 molar equivalents
of pentyne (catalog no. Wako 322-49451, Wako Chemicals,
Richmond, VA), 0.2mol equivalents of aqueous CuSO4, and 0.4
mol equivalents of L-sodium ascorbate were added to 1 molar
equivalent peracetylated -xylosyl azide. The reaction product,
click-xyloside, was purified on a flash silica column using an
ethyl acetate-hexane gradient. The purified product was subse-
quently deprotected in dryMeOH/sodiummethoxide at pH10.
The deprotected compound was purified on a reverse phase
silica column to obtain the final product, MQ-1-31, which was
characterized by 1H NMR and negative mode LC-MS.
HEK-293F cells stably expressing V-5GAG were seeded to
30% confluence and incubated for 16 h in medium supple-
mented with 10% FBS and antibiotics. The cells were washed
with PBS, and the medium was replaced with serum-free
medium containing click-xyloside (dissolved in dimethyl sulf-
oxide) at a stock concentration of 10 mM) at the appropriate
concentration. For controls, the appropriate amount of
dimethyl sulfoxide was added to the medium. After 48 h of
further culture, the conditionedmediumwas collected, and the
effect of increasing click-xyloside concentration on V-5GAG
cleavage by ADAMTS5 was determined.
V-5GAG Pulldown by the ADAMTS5 Ancillary Domain—
Anti-FLAG-agarose beads (50 l) were washed three times
with TBS, added to conditioned medium containing the
ADAMTS5 ancillary domain, and incubated at room tempera-
ture for 2 h. The resin was washed five times with TBS (150mM
NaCl and 50 mM Tris-HCl (pH 7.6)), added to V-5GAG condi-
tioned medium, and incubated at room temperature for a fur-
ther 2 h. The resin was washed five times with TBS and resus-
pended to a volume of 100 l with TBS prior to digestion with
chondroitinase ABC (0.1 units/ml) at 37 °C for 2 h. The super-
natant was analyzed by Western blotting for V-5GAG using
anti-VC. A control pulldown assay was performed using the
medium of cells transfected with an empty vector (p3XFLAG-
CMV9) instead of the ADAMTS5 ancillary domain condi-
tioned medium. The purpose of this control was to show that
V-5GAG was not binding nonspecifically to the anti-FLAG-
agarose beads.
Particle Exclusion Assay—The RBC exclusion assay was used
to visualize the pericellular matrix and was carried out essen-
tially as described previously (10). Briefly, formalin-fixed sheep
RBCs were washed with PBS and resuspended to a final con-
centration of 1.0  108 RBCs/ml. Dermal fibroblasts obtained
3 J. Larkin, T. A. Lohr, L. Elefante, J. Shearin, R. Matico, J.-L. Su, Y. Xue, F. Liu, C.
Genell, R. E. Miller, P. B. Tran, A.-M. Malfait, C. C. Maier, and C. J. Matheny,
manuscript submitted.
4 M. T. Dours-Zimmermann and D. R. Zimmermann, unpublished data.
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from wild-type C57Bl/6J mice were plated at30% confluence
in 6-well plates and incubated in serum-free medium with
anti-VC or control rabbit isotype-matched IgG antibody for
24 h. TheRBC suspension (200l) was added to eachwell along
with calcein (final concentration 1 g/ml) for cell visualization
and incubated for 20min to allow the RBCs to settle around the
cells. Images of the cells were taken with an inverted wide-field
Leica microscope (DR IRB, Heidelberg, Germany) using a20
objective lens in fluorescent and phase-contrast modes. Peri-
cellular matrix exclusion zones were quantified using ImageJ
(Media Cypernetics, Silver Spring, MD) by subtracting the area
of the fluorescent image (i.e. the cell) from the total area of the
cell plus the exclusion zone as observed in phase-contrast
mode.
Collagen Gel Contraction Assay—The collagen gel contrac-
tion assay was performed as described previously (10). Melted
4% agarose (Amresco, Solon, OH) was allowed to gel in 24-well
plates around 10-mm cloning rings to form 10-mm diameter
molds for the collagen gels. Rat tail collagen (3.2mg/ml, catalog
no. 354236, BD Biosciences) was diluted to a final concentra-
tion of 1.6mg/ml with DMEMcontaining 10% FBS, antibiotics,
and dermal fibroblasts (2 105 cells). Antibody (either anti-VC
or rabbit IgG isotype-matched control) was added at the appro-
priate concentration, and the gelswere allowed to polymerize at
37 °C for 1 h. The gels were overlaid with 1 ml DMEM supple-
mented with 10% FBS, antibiotics, and either anti-VC or the
control antibody at the appropriate concentration. The gels
were detached from the agarose mold and allowed to contract
overnight (16 h) at 37 °C as suspended gels. The gels were visu-
alized under a stereomicroscope, and the area was quantified
using ImageJ.
Statistical Analysis—Data represent the mean  S.D. of at
least three independent experiments. Statistical analysis was
performed using the unpaired Student’s t test.
RESULTS
The Glu441-Ala442 Bond Is a Major Site of Versican Proteoly-
sis in the Versican GAG Domain—New human versican-V1
constructs (Fig. 1A) and a new versican antibody to a peptide
straddling the Glu441-Ala442 bond, named anti-VC, were gen-
FIGURE1.Characterizationofversicanconstructsused for this analysis.A, domain compositionof constructs showing theglobular domainsG1andG3and
the CS-bearing GAG domain specific for versican-V1. The peptide used as the immunogen for anti-VC is shown. The arrows indicate the ADAMTS-targeted
Glu441-Ala442 peptide bond. B, Western blot analysis with the indicated antibodies following reducing SDS-PAGE showing versican-V1 expression in condi-
tionedmediumand characteristically improveddetection after digestionwith chondroitinaseABC (CABC). IB, immunoblot.C, detection of V-5GAGexpression
by the indicated antibodies. In B and C, chondroitinase ABC was necessary to resolve the proteoglycan as a sharper band and allow it to migrate fully into the
resolving gel. D, ADAMTS5 cleavage of versican-V1 and V-5GAG detected using anti-VC. Bands relating to versikine or intact proteoglycan are indicated with
one or two asterisks, respectively.
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erated to facilitate this analysis. Western blotting of full-length
versican (V1) and V-5GAG transfected into HEK293F cells
demonstrated that they were modified appropriately with CS
chains because a high molecular weight smear arising from
each was resolved into a sharper band of stronger intensity fol-
lowing chondroitinaseABCdigestion (Fig. 1,B andC). Anti-VC
detected versican-V1 and V-5GAG specifically after digestion
with chondroitinase ABC, with a reactivity similar to commer-
cial anti-GAG and anti-myc antibody onWestern blot analy-
ses (Fig. 1, B and C). The specificity of anti-VC was validated
by blockade of its reactivity against V-5GAG on Western blot
analyses after incubation with the peptide immunogen (data
not shown). Without chondroitinase ABC digestion, as
expected, versican-V1 and V-5GAG migrated poorly into the
gel or not at all (Fig. 1,B andC). V-5GAG,which contains fewer
CS chains thanV1 and is smaller, was detectable using anti-myc
but not anti-VC (Fig. 1C). The observed difference likely results
from differences between the affinities and optimal concentra-
tions of the two antibodies in these Western blot analyses.
V-5GAG, but not V1, was detectable by anti-myc on Western
blot analyses (Fig. 1C and data not shown for V1), despite the
cloning of theV1-ORF in-framewith themyc-His6 tag, possibly
because of proteolytic loss of the tag in the latter construct. In
subsequent experiments, we used anti-GAG for detection of
V1, anti-myc for detection of V-5GAG, and anti-VC for detec-
tion of either construct. When either versican-V1 or V-5GAG
were digestedwithADAMTS5-containingmedium, but not the
medium of vector-transfected cells, and the digests were
FIGURE 2. Characterization of anti-DPEAAE and recombinant human versikine. A, competitive solid-phase binding assay examining the reactivity of
anti-DPEAAE. Versikinewas coated in eachwell anddetectedby anti-DPEAAE antibodypreincubatedwith the indicatedpeptides at increasing concentrations
(data points are shown as mean  S.E., n  6). Peptides other than DPEAAE do not block anti-DPEAAE effectively. B, representative Western blot analyses
contrasting versikine and versikine-myc immunoreactivity to anti-VC (left panel) and anti-DPEAAE (right panel). Anti-DPEAAE fails to detect versikine-myc as a
consequence of epitope masking by the myc tag. IB, immunoblot. C, representative Western blot analysis showing the change in migration of versikine-myc
following peptide N-glycanase F (PNGase F) treatment. D, representative Western blot analysis demonstrating that ADAMTS5 does not cleave versikine.
Versikine (left panel) and versikine-myc (right panel) were incubatedwith ADAMTS5 or empty vector control conditionedmediumandprobedwith anti-VC. No
change in molecular species was observed following ADAMTS5 treatment.
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treated with chondroitinase ABC, a 70-kDa band correspond-
ing to versikine was obtained (Fig. 1D). ADAMTS5 cleaved
versican upon coincubation of a versican construct with
ADAMTS5 conditionedmedium as well as after cotransfection
of ADAMTS5 and versican constructs.
We evaluated the specific immunoreactivity of anti-
DPEAAE to versikine by preincubating the antibody with a
variety of peptides, such as those that deleted Glu441 (DPEAA),
replaced it with Ala (DPEAAA), or added one or two C-termi-
nal Ala residues (DPEAAEA, DPEAAEAA). Neither of these
peptides blocked anti-DPEAAE reactivity against versikine as
effectively as peptide DPEAAE (Fig. 2A). Anti-DPEAAE failed
to react with versikine when a C-terminal myc-His6 tag was
present (Fig. 2B). In contrast, anti-VC could detect versikine or
versikine-myc-His6 with similar reactivity on Western blot
analyses. Therefore, anti-DPEAAE is a true neoepitope anti-
body to versikine that is absolutely dependent on Glu441 for its
reactivity, whereas anti-VC detects versikine because it con-
tains 10 of the 14 immunogen peptide residues (Fig. 1A). As
shown in Fig. 1, anti-VC can detect versikine in samples elec-
trophoresed without prior chondroitinase ABC digestion as
well as intact versican substrate if the sample is digested prior to
electrophoresis (Fig. 1, B–D). In subsequent experiments, we
used anti-DPEAAE or anti-VC to detect versikine but did not
use anti-DPEAAE for analysis of cleavage site mutants because
of its stringent specificity.
Consistentwith previous reports, versikinemigrated electro-
phoretically with an observedmolecularmass of70 kDa (Figs.
1D and 2, B–D), which was inconsistent with its predictedmass
of 48.9 kDa. Because versikine lacks CS chains, we digested it
with peptide N-glycanase F to determine whether the discrep-
ancy could be explained bymodification at three potential sites
for N-glycosylation, i.e. Asn57, Asn330, and Asn411. When
treated with peptide N-glycanase F, the observed molecular
mass was reduced by5 kDa (Fig. 2C). The presence of a highly
negatively charged region (amino acids 361–408) in versikine
likely leads to local intrinsic disorder that can manifest as aber-
rant migration in SDS-PAGE. Indeed, analysis of the sequence
of versikine using online prediction tools (IUPreD and FoldIn-
dex) predicted a strong tendency to local disorder in residues
360–441. When versikine or myc-tagged versikine were
digested with ADAMTS5 and the digests were immunoblotted
with anti-VC, versikine migration was unchanged, suggesting
that, when released from versican, versikine was not cleaved
further by ADAMTS5 (Fig. 2D).
To investigate whether cleavage occurred at additional sites
within the GAG domain, we analyzed ADAMTS5-digested
versican-V1 byWestern blotting with four polyclonal antibod-
ies spanning theGAG-domain (Fig. 3A). AntibodyA, themost
N-terminal and adjacent to the G1 domain, detected a 70-kDa
band similar to anti-VCwhen either V1 or V-5GAGwere incu-
batedwithADAMTS5 (Fig. 3B). This species likely corresponds
FIGURE 3.GAG cleavagebyADAMTS5occurs at theGlu441-Ala442 site.A, locations of peptides used as immunogens for a series of rabbit polyclonal rabbit
antisera GAG A-D are indicated. The arrow shows the location of the Glu441-Ala442 cleavage site. B, Western blot analyses of ADAMTS5 digests of versican-V1
(using antibodies GAGA-GAGD) or V-5GAG (using antibodies GAGA and GAGB) following chondroitinase ABC digestion and reducing SDS-PAGE. Con-
ditionedmediumobtained fromempty vector-transfected cellswas the control. The expected locations of versican-V1, V-5GAG, and versikine are indicated. IB,
immunoblot.
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to versikine because the peptide used to generate antibody A,
like the VC peptide, spans the Glu441-Ala442 processing site.
However, antibodies B-D did not identify fragments resulting
specifically from digestion with ADAMTS5 (Fig. 3B). We con-
clude that ADAMTS5 did not process the versican GAG core
protein at sites other than Glu441-Ala442. However, fragments
not resulting from ADAMTS5 digestion (i.e. observed in both
the experimental and control lanes) were seen, suggesting that
versican may be cleaved by other proteases expressed by
HEK293F cells (Fig. 3B).
The ADAMTS5 Ancillary Domain Binds to Versican-V1 and
Is Essential for Proteolysis—To determine which region of
ADAMTS5 bound to versican, we utilized a construct contain-
ing the propeptide, catalytic domain, and disintegrin-like domain
(ADAMTS5Pro-Cat-Dis) or the entire ancillary domain (Fig. 4A).
In contrast to full-lengthADAMTS5,ADAMTS5Pro-Cat-Dis did
not cleave versican V5-GAG, suggesting a requirement of the
ancillary domain for versican binding (Fig. 4B). To investigate
whether the ancillary domain promoted versican cleavage by
localizing ADAMTS5 to the versican core protein, coimmuno-
precipitation was performed. The FLAG epitope-tagged
ADAMTS5 ancillary domain was first successfully pulled down
using anti-FLAG-agarose beads (Fig. 4C). The FLAG resin 
ancillary domain complex was incubated with V-5GAG condi-
tioned medium and washed extensively. The FLAG resin 
ancillary domain complexes were incubated with chondroiti-
nase ABC, and the supernatant was analyzed by Western blot-
ting using anti-VC. A coprecipitating band of150 kDa corre-
sponding toV-5GAGwas observed (Fig. 4D). This bandwas not
seen when immunoprecipitation was performed using empty
vector-transfected conditioned medium as a control. There-
fore, the ancillary domain of ADAMTS5 interacted specifically
with V-5GAG via the CS chains.
Versican Chondroitin Sulfate Chains Are Required for Prote-
olysis by ADAMTS5—When either versican-V1 or V-5GAG
were digested with chondroitinase ABC prior to incubation
with ADAMTS5, there was a substantial reduction in band
intensity of versikine (Fig. 5A), suggesting that CS chains play a
central role in mediating ADAMTS5 proteolysis at the Glu441-
Ala442 site. Because V-5GAG digestion by ADAMTS5 gave a
comparable versikine product, as did a digest of versican-V1
(Figs. 1D and 5A), we considered it likely that V-5GAG con-
tained the determinant(s) necessary for processing at Glu441-
Ala442. We compared proteolysis of V-5GAG expressed in
FIGURE 4. The ADAMTS5 ancillary domain binds versican-V1. A, schematic of the ADAMTS5 constructs used. B, Western blot analysis obtained under
reducing conditions showing that, in contrast to full-length ADAMTS5, ADAMTS5-Pro-Cat-Dis does not cleave versican V-5GAG. IB, immunoblot. C, Western
blot analysis showingpulldownof theADAMTS5ancillary domainusing anti-FLAGbeads.D, V-5GAG is pulleddownalongwith theADAMTS5ancillary domain.
The V-5GAG input protein is electrophoresed at the left to provide a size standard for the coeluting V-5GAG seen in the far right lane.
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CHO-K1 cells and themutant derivative cell line, CHO-K1pgs-
745A,which lacks xylosyltransferase and is, therefore, unable to
addGAGchains to core proteins. ADAMTS5did not efficiently
cleave V-5GAG expressed from CHO-K1 pgs745A cells,
despite comparable levels of core protein secreted from
CHO-K1 or CHO-K1 pgs745A cells (Fig. 5B). In addition,
digests of V-5GAG from CHO cells cultured in the presence of
a click-xyloside, which reduces GAG-attachment to core pro-
teins, demonstrated a dose-dependent reduction of versikine
production relative to the amount of V5-GAG secreted by the
cells (Fig. 5C). Together, these results clearly indicate a key
role for the CS chains in mediating ADAMTS5 cleavage of
versican.
To determine whether specific CS chains of V-5GAG medi-
ated ADAMTS5 cleavage, we mutated four of the CS attach-
ment sites (Fig. 6A). Loss of individual GAG attachment sites
did not affect the secretion efficiency of the respectivemutants, as
evident from comparable levels of each mutant in the medium of
transfected cells (Fig. 6B, bottom panel). However, loss of two CS
chains nearest the Glu441-Ala442 scissile bond (i.e.mutagenesis of
FIGURE 5. CS modification of the versican-V1 core protein is essential for processing at the Glu441-Ala442 site. A, representative Western blot analyses
showing theeffect of theCSmodificationon the susceptibility of versican-V1andV-5GAG toproteolysis byADAMTS5.A strongversikineband (asterisks) is seen
onlywhen the versican substratewasnot treatedwith chondroitinaseABC (CABC) prior todigestionwithADAMTS5. IB, immunoblot.B, V-5GAGwas expressed
in CHO-K1 cells or the pgs745A CHO-K1mutant lacking xylosyltransferase and incubatedwith conditionedmedium containing ADAMTS5. Top panel, reduced
versikine generation from substrate obtained from pgs745A cells, which is also visualized better than that which is from CHO-K1 cells without chondroitinase
ABC treatment because it lacks CS chains. Bottom panel, obtained after chondroitinase ABC treatment and showing comparable levels of V-5GAG secreted by
each cell line. C, click-xyloside addition reduces versican cleavage dose-dependently. Left panel, top left, representative Western blot analysis of ADAMTS5
digests of V-5GAG expressed in the presence of increasing concentrations of click-xyloside without subsequent chondroitinase ABC digestion. Versikine is
indicated by the asterisk. Note that V-5GAG was poorly visualized until cells were treated with 200 M xyloside. Left panel, bottom, Western blot analysis of
chondroitinase ABC-treated conditionedmedia demonstrating that V-5GAG expressionwas unaffected by addition of click-xyloside. Right panel, the decrease
in versikine intensity was normalized to V-5GAG expression and quantified, confirming the click-xyloside-mediated, dose-dependent decrease in V-5GAG
cleavage. All data are mean S.E. of three experiments. **, p 0.005.
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Ser507 and Ser525) led to a statistically significant reduction in ver-
sikine product. Elimination of CS attachment to Ser644 or Ser646
(by mutating Gly645) and Ser655 was without a similar effect (Fig.
6B). Therefore, we conclude that the two most N-terminal CS
chains are required for processing byADAMTS5.To test this pos-
sibility, versicanase digests were undertaken using V-2GAG, a
construct containingonly the twoN-terminalCS attachment sites
identified as crucial after mutagenesis of V5-GAG, i.e. Ser507 and
Ser525 (Fig. 6C). This construct was cleaved efficiently by
ADAMTS5 (Fig. 6C).We conclude that the CS chains attached to
Ser507 and Ser525 are necessary and sufficient for versican-V1
processing by ADAMTS5.
FIGURE 6. The twoN-terminal-most CS chains are essential for versican proteolysis at the Glu441-Ala442 site. A, schematic depicting themutants used in
this analysis. The locations of the individual mutations that abolish CS attachment are shown by the dotted line. Solid lines indicate CS chain attachment sites
that were not mutated in the respective constructs. B, representative Western blot analysis of V-5GAG mutants after digestion with ADAMTS5. Note the
reduction of versikine specifically in the Ser507 and Ser525 mutants. Top panel, bottom, Western blot analysis with anti-myc illustrating the amounts of each
mutant that were used in the analysis and that the mutations did not substantially affect secretion. For detection of V5-GAG by anti-myc, samples were
enzymatically deglycosylated with chondroitinase ABC prior to electrophoresis. Bottom panel, quantitative analysis of Western blot analyses from three
independent experiments. *, p 0.05. C, Western blot analysis of the V-2GAG construct (top panel) digestedwith ADAMTS5 or vector-conditionedmedium as
a control for ADAMTS5. V2-GAG was modified by CS attachment (bottom left panel) and underwent efficient digestion by ADAMTS5 to generate versikine
(bottom right panel). CABC, chondroitinase ABC.
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Recently, a novel versican isoform, V4, which arises by use of a
cryptic splice site in the GAG-encoding exon, was described. V4
containsG1,G3, and the fiveN-terminalCS-attachment sites. It is
essentially similar to the V-5GAG construct other than having a
C-terminal G3 domain. A V4 construct was processed by
ADAMTS5 comparably with V-5GAG (data not shown).
Glu441 Is Required for Versican Proteolysis by ADAMTS5—In
view of the prevalence of Glu as the P1 residue in peptide
bonds cleaved by ADAMTS proteases in aggrecan and ver-
sican (35, 39), we asked whether proteolysis of V-5GAG was
affected when Glu441 was mutated (to Ala) (Fig. 7A). This
mutant was secreted into medium of transfected cells at
comparable levels as V-5GAG (Fig. 7B), but its digestion by
ADAMTS5 was reduced substantially (Fig. 7C). Instead, an
anti-VC reactive fragment was observed that migrated
slightly more rapidly, suggestive of proteolysis at a site
immediately upstream, i.e. following Glu438. When both
Glu438 and Glu441 were mutated, however, no digestion of
V-5GAG occurred, as detected by both anti-VC and an anti-
body to the versican G1 domain (Fig. 7C). Notably, these
mutations did not abolish versican recognition by anti-VC
(Fig. 7B, compare top and bottom panels).
Anti-VC Blocks Versican Processing—Because the anti-
VC immunogen peptide straddles the Glu441-Ala442 cleavage
site, we asked whether anti-VC antibody binding to ver-
sican could sterically hinder its proteolysis. Incubation of
V-5GAG with anti-VC demonstrated a dose-dependent
accumulation of undigested V-5GAG (Fig. 8A) and reduced
the versikine product in the digests (Fig. 8B), indicative of
inhibition of versican proteolysis. Previously, loss of
ADAMTS5 activity in skin fibroblasts has been shown to
lead to an accumulation of a versican-rich pericellular
matrix and a fibroblast-to-myofibroblast transition (10).
When wild-type mouse skin fibroblasts were treated with
anti-VC, there was an accumulation of pericellular matrix
(Fig. 9A) and enhanced contractility of dermal fibroblasts in
collagen gels (Fig. 9B). This effect of anti-VC, similar to that
demonstrated previously upon inactivation of ADAMTS5 or
overexpression of versican-V1 (10), suggests that anti-VC
can be used to block versican proteolysis by ADAMTS5.
ADAMTS1Has Similar Requirements forVersicanProcessing
as ADAMTS5—ADAMTS1 proteolysis of versican is required
for ovulation (53, 54) and for compaction of the developing
myocardium (55). Here we extend the major findings of our
investigation to ask whether ADAMTS1 employed similar
mechanisms as ADAMTS5 for versican processing. Like
ADAMTS5, ADAMTS1 could generate versikine when
V-5GAG was generated in CHO-K1 cells but not in xylosyl-
FIGURE 7. Mutations in the vicinity of the Glu441-Ala442 bond reveal a proximate upstream site that is cleaved with lower efficiency. A, schematic
showing the amino acid substitutions employed in mutagenesis around the Glu441-Ala442 site (arrow). B, Western blot analysis of conditioned medium with
anti-VC or anti-myc showing secretion of themutant constructs. Themedia were treatedwith chondroitinase ABC prior to electrophoresis. Comparison of the
two panels (anti-VC and anti-Myc) suggests that the mutations did not substantially impair recognition by anti-VC. IB, immunoblot. C, Western blot analysis
showing the effect of these mutations on digestion by ADAMTS5. A product migrating slightly more rapidly than versikine, and surmised to result from
cleavage of the Glu438-Ala439 peptide bond, is seen following mutation of Glu441 (the new molecular species is indicated by asterisks). Cleavage at this site is
inhibited followingmutation of Glu438 as well as Glu441 (V-5GAG(B) and V-5GAG(C), respectively). A Western blot analysis using a G1 domain-specific antibody
(right panel) confirmed that these mutants were detectable using anti-VC and that they had reduced or absent processing.
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transferase-deficient pgs-745A cells (Fig. 10A). Further-
more, mutation of Glu441 and Glu438 abrogated versican
processing by ADAMTS1 (Fig. 10B), and prevention of GAG
attachment at Ser507 and Ser525 by mutagenesis of these res-
idues also prevented or reduced proteolysis by ADAMTS1
(Fig. 10C).
DISCUSSION
Because of the great interest in characterizing ADAMTS4
and ADAMTS5 activity in osteoarthritis, proteolysis of aggre-
can, the major cartilage proteoglycan, has been investigated
extensively (39, 40). However, the mechanisms of versican
cleavage have not been investigated previously. This analysis,
focusing on ADAMTS5 and ADAMTS1, which are major ver-
sicanases during embryogenesis, demonstrates similarities and
distinctions between ADAMTS proteolysis of versican and
aggrecan. These studies show that, unlike aggrecan, which is
cleaved by ADAMTS proteases, including ADAMTS5, at mul-
tiple sites within the CS-bearing domain (39, 40), cleavage of
the versican-V1 core protein primarily occurred at the Glu441-
Ala442 site or, in its absence, at a putative upstream site but not
elsewhere within the GAG-domain.
Wehave shownhere that ADAMTS5 relies on specific deter-
minants in versican for interaction and proteolysis respectively,
i.e. two specific CS chains andGlu441. These findings constitute
the first understanding of how versican is cleaved by an
ADAMTSprotease. Initially, the analysis showed that enzymat-
ically eliminating CS modification of the core protein led to
reduced proteolysis. Because digestion by chondroitinase ABC
leaves residual core oligosaccharide stubs, we sought additional
evidence using CHO-pgs745A cells, which lack the ability to
attach xylose (51), the first residue of the nascent CS chain.
Reduced ADAMTS5 and ADAMTS1 proteolysis of V-5GAG
expressed by these cells or by cells cultured in the presence of a
click-xyloside that acts as a decoy for CS attachment (52) sup-
ported the requirement of CS chains in V-5GAG for proteoly-
sis. We conclude that the two N-terminal-most CS chains are
likely binding sites for ADAMTS5 exosites and provide it with
access to the Glu441-Ala442 site. ADAMTS5 binding to the CS
chains could lead to a conformational change in the versican
core protein that renders the Glu441-Ala442 site accessible or
contributes to opening of the ADAMTS5 catalytic site, previ-
ously shown to exist in both open and closed conformations
(56).
Previously, an Escherichia coli-expressed, GAG-free versican
polypeptide spanning residues Gly357 to Asp567 has been used to
demonstrateproteolytic processingof versicanbyADAMTS1and
ADAMTS4 (35). In contrast, our work suggests that CS-modified
versican is the preferred ADAMTS5 and ADAMTS1 substrate.
We speculate that the CS-chains provide an anchorage site
near the scissile bond that may be otherwise elusive in a
polypeptide that is predicted to be unstructured. At the scis-
sile bond, Glu441 was an essential determinant, and its elim-
FIGURE 8. Versican cleavage by ADAMTS5 is inhibited by anti-VC. A, V-5GAG remaining after incubation with ADAMTS5 in the presence of anti-VC is
detected by Western blotting using anti-myc. For reasons that are not understood, the expected myc-tagged C-terminal fragment resulting from proteolysis
is not detected by anti-myc. Right panel, quantification of intact V-5GAG observed with increasing concentrations of anti-VC (results are from three indepen-
dent experiments). IB, immunoblot. B, digestion of V-5GAGbyADAMTS5 in the presence of anti-VC results in a dose-dependent reduction of versikine product
(arrow). Theasterisk shows theanti-VC IgGheavy chain that reactedwith theanti-rabbit secondary antibodyused for theWesternblot analysis.Right panel, data
were quantified and plotted as the mean S.E. of three experiments. *, p 0.05; **, p 0.005.
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FIGURE 9.Anti-VC induces the accumulation of pericellular matrix andmyofibroblast transition inmouse dermal fibroblasts. A, erythrocyte exclusion
assay demonstrating increased pericellular matrix around dermal fibroblasts in the presence of anti-VC. Arrows indicate the pericellular matrix border around
calcein-labeled fibroblasts (green). Representative images are shown for both control IgG and anti-VC. Quantification of pericellular matrix area demonstrates
a significant increase in anti-VC treated cells (p 0.005), as shown in the whisker plot (bottom panel), attributed to reduction in versican cleavage. Each dot in
the plot is a single cell measurement. B, collagen contraction assay to evaluate fibroblast contractility in the presence of anti-VC. Representative images are
shown in the top panel. Quantification of the gel area demonstrates a significant reduction in the presence of anti-VC (p  0.005), suggestive of increased
contraction of the collagen gel by embedded fibroblasts (bottom panel). Each dot in the plot represents a single gel.
FIGURE 10.ADAMTS1 cleavage of V-5GAG uses similar molecular determinants as ADAMTS5. A, versican and V-5GAGwere expressed in CHO-K1 cells or
the pgs745A CHO-K1 mutant (as shown in Fig. 5) and incubated with conditioned medium containing ADAMTS1. A reduction in versikine generation was
observed using V-5GAG expressed in pgs745A CHO-K1 cells. CABC, chondroitinase ABC; IB, immunoblot. B, Western blot analysis showing the effect of the
cleavage site mutants (described in Fig. 7) on digestion by ADAMTS1. Cleavage, speculated to occur after Glu438, is observed in mutant A (indicated by the
asterisk). Cleavage at this site is eliminated following mutation of Glu438 (V-5GAGB). C, representative Western blot analysis of V-5GAG CS chain attachment
mutants (described in Fig. 6) after digestion with ADAMTS1 followed by chondroitinase ABC treatment. The two CS chain attachment mutants that had
reduced cleavage byADAMTS5 also had reducedADAMTS1-mediated versican cleavage (versikine is indicated by the asterisk). A chondroitinase ABCdigest of
the V-5GAG conditioned medium shows comparable expression levels of all constructs.
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ination led to cleavage at a site immediately upstream, which
we posit to be the Glu438-Ala439 bond. The precise site could
not be determined because of the low prevalence of the alter-
native cleaved fragment and the inherent difficulty of C-ter-
minal protein sequencing.
ADAMTS4 and ADAMTS5 cleave aggrecan not only within
the interglobular domain but also at several other sites within
the GAG-bearing region (39, 40, 57). Aggrecan has a higher
density of GAG attachment sites than versican, and the GAG
attachment region is divided into an N-terminal CS1 and a
C-terminal CS2 domain (58). Addition of glycosaminoglycan
sugars to articular explant cultures inhibitedADAMTS1, 4, and
5 activities, presumably by competing with the GAGs on aggre-
can (59).
Previous work examining ADAMTS4 cleavage of aggrecan
had not identified specific CS chains as crucial determinants of
proteolysis within the CS2 region (60, 61). However, the
requirement for the ancillary domain has been established for
ADAMTS4 and ADAMTS5 cleavage of aggrecan (62, 63) and
appears to be similar for cleavage of versican. Therefore, the
ADAMTS5 ancillary domain, on the basis of its binding to the
CS chains, likely contains one or more exosites for ADAMTS5
activity against aggrecan and versican. Such exosites are neces-
sary because the catalytic domains of ADAMTS proteases typ-
ically have little activity against native substrates, and most
binding attributes are located in the ancillary domain. For
example, ADAMTS1 binding to the extracellular matrix was
dependent on its ancillary domain (64), TSR1 ofADAMTS4has
been shown to be essential for aggrecanase activity through
binding to the CS chains (61), and truncation experiments as
well as chimeric proteins of ADAMTS4 and ADAMTS5 have
shown altered activity against aggrecan after manipulation of
the ancillary domains (63, 65). Furthermore, the crystal struc-
ture of the ADAMTS13 ancillary domain in conjunction with
mutagenesis suggested the presence of several discontinuous
exosites for its substrate von Willebrand factor (66). The
importance of exosites in substrate recognition is particularly
evident in thrombotic thrombocytopenic purpura, where
autoantibodies are commonly directed to ADAMTS13 exo-
sites, inhibiting substrate recognition and reducing von Will-
ebrand factor processing (67, 68).
Anti-DPEAAE antibody is a widely used and valuable tool for
versican analysis (10, 16, 17, 33, 35, 42, 44–46, 53, 56–58), but
the determinants of its reactivity have not been mapped previ-
ously. Our finding that Glu441 was absolutely required for anti-
DPEAAE reactivity necessitated the development of an anti-
body for this work whose reactivity was not dependent on the
presence ofGlu441. As shownhere, anti-VC retains its reactivity
and specificity after mutagenesis of both Glu441 and Glu438.
Furthermore, we have shown that anti-VC is function-blocking
for proteolysis by ADAMTS5 and can be used to manipulate
versican processing in vitro and, potentially, in vivo. Applied to
skin fibroblasts, anti-VC has effects similar to those elicited
previously by genetic inactivation of ADAMTS5, i.e. accumula-
tion of pericellular matrix and a fibroblast-to-myofibroblast
phenotype switch demonstrated by enhanced contraction of a
collagen gel (10).
Previous work provided both genetic and biochemical evi-
dence strongly implicating versican proteolysis at the Glu441-
Ala442 site as a major mechanism underlying several ADAMTS
mouse mutant phenotypes. However, the conclusion that ver-
sican is their principal target can be unequivocally made only if
it can be shown that rendering versican uncleavable leads to
similar phenotypes. Thiswork provides information thatwill be
useful for resolution of this question. We identify three poten-
tially useful approaches for preventing versican processing, i.e.
elimination of GAG attachment at Ser507 and Ser525, replace-
ment of Glu441 by Ala, or administration of anti-VC blocking
antibody. Mousemodels incorporatingmutations at these sites
could be useful for rigorous evaluation of versican as the prin-
cipal Adamts1, Adamts5, Adamts20, and Adamts9 substrate in
cleft palate, soft tissue syndactyly, white spotting of skin, and
myocardial and valvular development.
This work provides a proof of principle for preventing cleav-
age of versican, aggrecan, and brevican by steric hindrance of
ADAMTS proteases using antibodies to the region of their scis-
sile bonds. Such an approach is potentially of therapeutic inter-
est in osteoarthritis for prevention of aggrecan proteolysis at
select sites and in gliomas for preventing cell migration and
invasion induced by ADAMTS-processed brevican (69, 70).
Indeed, for proteins cleaved bymultiple proteases, selective tar-
geting of a cleavage site in the manner demonstrated here may
be both more effective and less prone to side effects than pro-
tease blockade.
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